Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. While its approval was predated by two other members of the same drug family, namely ubrogepant and rimegepant, th...
Atogepant is indicated for the preventive treatment of migraine in adults by the FDA, EMA, and Health Canada.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.